Lung transplant recipients require life-long profound immunosuppression, making them prone to respiratory tract infections (RTIs), in particular viral infections, during the winter season. Since RTIs may have severe consequences, of which acute or chronic allograft dysfunction is feared most, early diagnosis and treatment are recommended. Patients monitor lung function daily at home and are instructed to contact the transplant center in case of signs and symptoms suspicious of RTIs. We then obtain nasopharyngeal swabs for viral and bacteriological examination and initiate pre-emptive treatment with antivirals, broadband antibiotics, and sometimes intravenous immunoglobulins. Treatment duration is guided by virology sampling results. As prev...
The epidemiology of respiratory viruses (RVs) in lung transplant recipients (LTRs) and the relations...
BACKGROUND: Respiratory syncytial virus (RSV) infections in lung transplant recipients (LTRs) have b...
Lung transplantation has become an accepted treatment for end-stage pulmonary parenchymal and vascul...
Solid organ transplantation is often lifesaving, but does carry an increased risk of infection. Resp...
Lung transplant recipients have a life-long profound immunosuppression which makes them prone to res...
Viral infections account for up to 30% of all infectious complications in lung transplant recipients...
BACKGROUND: The incidence and outcomes of respiratory viral infections in lung transplant recipients...
BACKGROUND: The incidence and outcomes of respiratory viral infections in lung transplant recipients...
Lung transplant recipients are at greater risk of respiratory viral infections as compared to other ...
Background. Chronic lung allograft dysfunction (CLAD) is the major limiting factor for long-term sur...
The epidemiology of respiratory viruses (RVs) in lung transplant recipients (LTRs) and the relations...
The epidemiology of respiratory viruses (RVs) in lung transplant recipients (LTRs) and the relations...
Respiratory syncytial virus (RSV) infections in lung transplant recipients (LTRs) have been associat...
Viral infections account for up to 30% of all infectious complications in lung transplant recipients...
The epidemiology of respiratory viruses (RVs) in lung transplant recipients (LTRs) and the relations...
The epidemiology of respiratory viruses (RVs) in lung transplant recipients (LTRs) and the relations...
BACKGROUND: Respiratory syncytial virus (RSV) infections in lung transplant recipients (LTRs) have b...
Lung transplantation has become an accepted treatment for end-stage pulmonary parenchymal and vascul...
Solid organ transplantation is often lifesaving, but does carry an increased risk of infection. Resp...
Lung transplant recipients have a life-long profound immunosuppression which makes them prone to res...
Viral infections account for up to 30% of all infectious complications in lung transplant recipients...
BACKGROUND: The incidence and outcomes of respiratory viral infections in lung transplant recipients...
BACKGROUND: The incidence and outcomes of respiratory viral infections in lung transplant recipients...
Lung transplant recipients are at greater risk of respiratory viral infections as compared to other ...
Background. Chronic lung allograft dysfunction (CLAD) is the major limiting factor for long-term sur...
The epidemiology of respiratory viruses (RVs) in lung transplant recipients (LTRs) and the relations...
The epidemiology of respiratory viruses (RVs) in lung transplant recipients (LTRs) and the relations...
Respiratory syncytial virus (RSV) infections in lung transplant recipients (LTRs) have been associat...
Viral infections account for up to 30% of all infectious complications in lung transplant recipients...
The epidemiology of respiratory viruses (RVs) in lung transplant recipients (LTRs) and the relations...
The epidemiology of respiratory viruses (RVs) in lung transplant recipients (LTRs) and the relations...
BACKGROUND: Respiratory syncytial virus (RSV) infections in lung transplant recipients (LTRs) have b...
Lung transplantation has become an accepted treatment for end-stage pulmonary parenchymal and vascul...